Primary Central Nervous System Non-Hodgkin Lymphoma
13
0
0
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.7%
1 terminated out of 13 trials
92.3%
+5.8% vs benchmark
0%
0 trials in Phase 3/4
25%
3 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (13)
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma